ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- Resumption of negotiations between ASIT biotech and DMS Thursday, 08 April 2021
- Cessation of negotiations Thursday, 18 March 2021
- The Walloon Region appeals against the judgment approving the judicial reorganisation plan of ASIT biotech Thursday, 25 February 2021 All ASIT news